Large-cap Health Care company DexCom has moved 0.1% so far today on a volume of 302,489, compared to its average of 4,736,973. In contrast, the S&P 500 index moved -0.0%.
DexCom trades -31.94% away from its average analyst target price of $99.71 per share. The 24 analysts following the stock have set target prices ranging from $83.0 to $115.0, and on average have given DexCom a rating of buy.
Anyone interested in buying DXCM should be aware of the facts below:
-
DexCom's current price is 435.6% above its Graham number of $12.67, which implies that at its current valuation it does not offer a margin of safety
-
DexCom has moved -2.6% over the last year, and the S&P 500 logged a change of 16.8%
-
Based on its trailing earnings per share of 1.42, DexCom has a trailing 12 month Price to Earnings (P/E) ratio of 47.8 while the S&P 500 average is 29.3
-
DXCM has a forward P/E ratio of 33.4 based on its forward 12 month price to earnings (EPS) of $2.03 per share
-
Its Price to Book (P/B) ratio is 10.34 compared to its sector average of 3.19
-
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
-
Based in San Diego, the company has 10,200 full time employees and a market cap of $26.61 Billion.